TGF-beta in CAF-mediated tumor growth and metastasis

Seminars in Cancer Biology

Volumn 25, Issue , 2014, Pages 15-22

  Calon, A ^a   Tauriello, D V F ^a   Batlle, E ^a,b  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Cancer associated fibroblast; Metastasis; Stroma; TGF beta; Tumor microenvironment

Indexed keywords

BELAGENPUMATUCEL L; BEVACIZUMAB; FRESOLIMUMAB; GALUNISERTIB; MARIMASTAT; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PRINOMASTAT; SIBROTUZUMAB; SORAFENIB; SUNITINIB; TANOMASTAT; TRABEDERSEN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

BIOLOGICAL THERAPY; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CARCINOMA ASSOCIATED FIBROBLAST; CELL DIFFERENTIATION; CELL SURVIVAL; CELL TYPE; COLORECTAL CANCER; FIBROBLAST; GLIOBLASTOMA; GLIOMA; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOLECULAR INTERACTION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PANCREAS CANCER; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR MICROENVIRONMENT; ANIMAL; METABOLISM; METASTASIS; NEOPLASMS; PARACRINE SIGNALING; PATHOLOGY; PHYSIOLOGY; TUMOR VOLUME;

ANIMALS; FIBROBLASTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASMS; PARACRINE COMMUNICATION; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 84897556892     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.12.008     Document Type: Review

References (132)

1. Huminiecki L., Goldovsky L., Freilich S., Moustakas A., Ouzounis C., Heldin C.H. Emergence, development and diversification of the TGF-beta signalling pathway within the animal kingdom. BMC Evol Biol 2009, 9:28.
2. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol 2012, 13(10):616-630.
3. Roberts A.B., Anzano M.A., Wakefield L.M., Roche N.S., Stern D.F., Sporn M.B. Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci USA 1985, 82(1):119-123.
4. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000, 1(3):169-178.
5. Chaffer C.L., Weinberg R.A. A perspective on cancer cell metastasis. Science 2011, 331(6024):1559-1564.
6. Ikushima H., Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 2010, 10(6):415-424.
7. Talmadge J.E., Fidler I.J. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 2010, 70(14):5649-5669.
8. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
9. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 133:3.
10. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003, 3(6):453-458.
11. Stover D.G., Bierie B., Moses H.L. A delicate balance: TGF-beta and the tumor microenvironment. J Cell Biochem 2007, 101(4):851-861.
12. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21(3):309-322.
13. Bauer M., Su G., Casper C., He R., Rehrauer W., Friedl A. Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast. Oncogene 2010, 29(12):1732-1740.
14. Navab R., Strumpf D., Bandarchi B., Zhu C.Q., Pintilie M., Ramnarine V.R., et al. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci USA 2011, 108(17):7160-7165.
15. Ostman A., Augsten M. Cancer-associated fibroblasts and tumor growth - bystanders turning into key players. Curr Opin Genet Dev 2009, 19(1):67-73.
16. Sugimoto H., Mundel T.M., Kieran M.W., Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 2006, 5(12):1640-1646.
17. Brentnall T.A., Lai L.A., Coleman J., Bronner M.P., Pan S., Chen R. Arousal of cancer-associated stroma: overexpression of palladin activates fibroblasts to promote tumor invasion. PLoS One 2012, 7(1):e30219.
18. Schoppmann S.F., Jesch B., Riegler M.F., Maroske F., Schwameis K., Jomrich G., et al. Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus. Clin Exp Metastasis 2013, 30(4):441-446.
19. Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999, 59(19):5002-5011.
20. Herrera M., Islam A.B., Herrera A., Martin P., Garcia V., Silva J., et al. Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows specific prognostic gene expression signature. Clin Cancer Res 2013, 19(21):5914-5926.
21. Desmouliere A., Guyot C., Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 2004, 48(5-6):509-517.
22. De Wever O., Demetter P., Mareel M., Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008, 123(10):2229-2238.
23. Matsumoto K., Nakamura T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer 2006, 119(3):477-483.
24. Pena C., Cespedes M.V., Lindh M.B., Kiflemariam S., Mezheyeuski A., Edqvist P.H., et al. STC1 expression by cancer-associated fibroblasts drives metastasis of colorectal cancer. Cancer Res 2013, 73(4):1287-1297.
25. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121(3):335-348.
26. Pietras K., Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 2010, 316(8):1324-1331.
27. Calon A., Espinet E., Palomo-Ponce S., Tauriello D.V., Iglesias M., Cespedes M.V., et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell 2012, 22(5):571-584.
28. Cirri P., Chiarugi P. Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev 2012, 31(1-2):195-208.
29. Dimanche-Boitrel M.T., Vakaet L., Pujuguet P., Chauffert B., Martin M.S., Hammann A., et al. In vivo and in vitro invasiveness of a rat colon-cancer cell line maintaining E-cadherin expression: an enhancing role of tumor-associated myofibroblasts. Int J Cancer 1994, 56(4):512-521.
30. Boire A., Covic L., Agarwal A., Jacques S., Sherifi S., Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005, 120(3):303-313.
31. Yu B., Chen X., Li J., Qu Y., Su L., Peng Y., et al. Stromal fibroblasts in the microenvironment of gastric carcinomas promote tumor metastasis via upregulating TAGLN expression. BMC Cell Biol 2013, 14:17.
32. Olaso E., Santisteban A., Bidaurrazaga J., Gressner A.M., Rosenbaum J., Vidal-Vanaclocha F. Tumor-dependent activation of rodent hepatic stellate cells during experimental melanoma metastasis. Hepatology 1997, 26(3):634-642.
33. Bandapalli O.R., Macher-Goeppinger S., Schirmacher P., Brand K. Paracrine signalling in colorectal liver metastases involving tumor cell-derived PDGF-C and hepatic stellate cell-derived PAK-2. Clin Exp Metastasis 2012, 29(5):409-417.
34. Grum-Schwensen B., Klingelhofer J., Berg C.H., El-Naaman C., Grigorian M., Lukanidin E., et al. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res 2005, 65(9):3772-3780.
35. Weiland A., Roswall P., Hatzihristidis T.C., Pietras K., Ostman A., Strell C. Fibroblast-dependent regulation of the stem cell properties of cancer cells. Neoplasma 2012, 59(6):719-727.
36. Vermeulen L., De Sousa E.M.F., van der Heijden M., Cameron K., de Jong J.H., Borovski T., et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010, 12(5):468-476.
37. Wang X.J., Liefer K.M., Tsai S., O'Malley B.W., Roop D.R. Development of gene-switch transgenic mice that inducibly express transforming growth factor beta1 in the epidermis. Proc Natl Acad Sci USA 1999, 96(15):8483-8488.
38. Shipley G.D., Pittelkow M.R., Wille J.J., Scott R.E., Moses H.L. Reversible inhibition of normal human prokeratinocyte proliferation by type beta transforming growth factor-growth inhibitor in serum-free medium. Cancer Res 1986, 46(4 Pt 2):2068-2071.
39. Barnard J.A., Beauchamp R.D., Coffey R.J., Moses H.L. Regulation of intestinal epithelial cell growth by transforming growth factor type beta. Proc Natl Acad Sci USA 1989, 86(5):1578-1582.
40. Moses H.L., Yang E.Y., Pietenpol J.A. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 1990, 63(2):245-247.
41. Siegel P.M., Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003, 3(11):807-821.
42. Jakowlew S.B. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 2006, 25(3):435-457.
43. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J., et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995, 268(5215):1336-1338.
44. Lu S.L., Zhang W.C., Akiyama Y., Nomizu T., Yuasa Y. Genomic structure of the transforming growth factor beta type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers. Cancer Res 1996, 56(20):4595-4598.
45. Grady W.M., Markowitz S.D. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 2002, 3:101-128.
46. Tsushima H., Kawata S., Tamura S., Ito N., Shirai Y., Kiso S., et al. High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996, 110(2):375-382.
47. Wikstrom P., Stattin P., Franck-Lissbrant I., Damber J.E., Bergh A. Transforming growth factor beta1 is associated with angiogenesis: metastasis, and poor clinical outcome in prostate cancer. Prostate 1998, 37(1):19-29.
48. Walker R.A., Dearing S.J. Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer 1992, 28(2-3):641-644.
49. Friedman E., Gold L.I., Klimstra D., Zeng Z.S., Winawer S., Cohen A. High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 1995, 4(5):549-554.
50. Cui W., Fowlis D.J., Bryson S., Duffie E., Ireland H., Balmain A., et al. TGFbeta1 inhibits the formation of benign skin tumors: but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996, 86(4):531-542.
51. Tang B., Vu M., Booker T., Santner S.J., Miller F.R., Anver M.R., et al. TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 2003, 112(7):1116-1124.
52. Glick A.B., Lee M.M., Darwiche N., Kulkarni A.B., Karlsson S., Yuspa S.H. Targeted deletion of the TGF-beta 1 gene causes rapid progression to squamous cell carcinoma. Genes Dev 1994, 8(20):2429-2440.
53. Hawinkels L.J., Paauwe M., Verspaget H.W., Wiercinska E., van der Zon J.M., van der Ploeg K., et al. Interaction with colon cancer cells hyperactivates TGF-beta signaling in cancer-associated fibroblasts. Oncogene 2014, 33:97-107.
54. Horiguchi M., Ota M., Rifkin D.B. Matrix control of transforming growth factor-beta function. J Biochem 2012, 152(4):321-329.
55. Shibahara K., Ota M., Horiguchi M., Yoshinaga K., Melamed J., Rifkin D.B. Production of gastrointestinal tumors in mice by modulating latent TGF-beta1 activation. Cancer Res 2013, 73(1):459-468.
56. Hawinkels L.J., Verspaget H.W., van der Reijden J.J., van der Zon J.M., Verheijen J.H., Hommes D.W., et al. Active TGF-beta1 correlates with myofibroblasts and malignancy in the colorectal adenoma-carcinoma sequence. Cancer Sci 2009, 100(4):663-670.
57. Kang Y., He W., Tulley S., Gupta G.P., Serganova I., Chen C.R., et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 2005, 102(39):13909-13914.
58. Padua D., Zhang X.H., Wang Q., Nadal C., Gerald W.L., Gomis R.R., et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008, 133(1):66-77.
59. Sethi N., Dai X., Winter C.G., Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 2011, 19(2):192-205.
60. Xu J., Lamouille S., Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009, 19(2):156-172.
61. Scheel C., Eaton E.N., Li S.H., Chaffer C.L., Reinhardt F., Kah K.J., et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011, 145(6):926-940.
62. Massague J. TGFbeta in Cancer. Cell 2008, 134(2):215-230.
63. Malanchi I., Santamaria-Martinez A., Susanto E., Peng H., Lehr H.A., Delaloye J.F., et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012, 481(7379):85-89.
64. Nguyen D.H., Oketch-Rabah H.A., Illa-Bochaca I., Geyer F.C., Reis-Filho J.S., Mao J.H., et al. Radiation acts on the microenvironment to affect breast carcinogenesis by distinct mechanisms that decrease cancer latency and affect tumor type. Cancer Cell 2011, 19(5):640-651.
65. Roman-Perez E., Casbas-Hernandez P., Pirone J.R., Rein J., Carey L.A., Lubet R.A., et al. Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients. Breast Cancer Res 2012, 14(2):R51.
66. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., et al. Type: density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313(5795):1960-1964.
67. Yang L., Pang Y., Moses H.L. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010, 31(6):220-227.
68. Li M.O., Wan Y.Y., Sanjabi S., Robertson A.K., Flavell R.A. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006, 24:99-146.
69. Liao D., Luo Y., Markowitz D., Xiang R., Reisfeld R.A. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 2009, 4(11):e7965.
70. Grivennikov S.I., Greten F.R., Karin M. Immunity: inflammation, and cancer. Cell 2010, 140(6):883-899.
71. Becker C., Fantini M.C., Schramm C., Lehr H.A., Wirtz S., Nikolaev A., et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004, 21(4):491-501.
72. Kim B.G., Li C., Qiao W., Mamura M., Kasprzak B., Anver M., et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 2006, 441(7096):1015-1019.
73. Pang Y., Gara S.K., Achyut B.R., Li Z., Yan H.H., Day C.P., et al. TGF-beta signaling in myeloid cells is required for tumor metastasis. Cancer discovery 2013, 3:936-951.
74. Evans R.A., Tian Y.C., Steadman R., Phillips A.O. TGF-beta1-mediated fibroblast-myofibroblast terminal differentiation-the role of Smad proteins. Exp Cell Res 2003, 282(2):90-100.
75. Shukla A., Edwards R., Yang Y., Hahn A., Folkers K., Ding J., et al. CLIC4 regulates TGF-beta-dependent myofibroblast differentiation to produce a cancer stroma. Oncogene 2013, Advanced Online Publication (AOP):18 February, 2013.
76. Kojima Y., Acar A., Eaton E.N., Mellody K.T., Scheel C., Ben-Porath I., et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci USA 2010, 107(46):20009-20014.
77. McDonald L.T., LaRue A.C. Hematopoietic stem cell derived carcinoma-associated fibroblasts: a novel origin. Int J Clin Exp Pathol 2012, 5(9):863-873.
78. Jotzu C., Alt E., Welte G., Li J., Hennessy B.T., Devarajan E., et al. Adipose tissue-derived stem cells differentiate into carcinoma-associated fibroblast-like cells under the influence of tumor-derived factors. Anal Cell Pathol (Amst) 2010, 33(2):61-79.
79. Zeisberg E.M., Potenta S., Xie L., Zeisberg M., Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 2007, 67(21):10123-10128.
80. Petersen O.W., Nielsen H.L., Gudjonsson T., Villadsen R., Rank F., Niebuhr E., et al. Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am J Pathol 2003, 162(2):391-402.
81. Oft M., Akhurst R.J., Balmain A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol 2002, 4(7):487-494.
82. Phillips R.J., Burdick M.D., Hong K., Lutz M.A., Murray L.A., Xue Y.Y., et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004, 114(3):438-446.
83. Wang H., Cao F., De A., Cao Y., Contag C., Gambhir S.S., et al. Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. Stem Cells 2009, 27(7):1548-1558.
84. Kidd S., Spaeth E., Dembinski J.L., Dietrich M., Watson K., Klopp A., et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009, 27(10):2614-2623.
85. Shinagawa K., Kitadai Y., Tanaka M., Sumida T., Kodama M., Higashi Y., et al. Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer 2010, 127(10):2323-2333.
86. Spaeth E.L., Dembinski J.L., Sasser A.K., Watson K., Klopp A., Hall B., et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009, 4(4):e4992.
87. Yang L., Chang N., Liu X., Han Z., Zhu T., Li C., et al. Bone marrow-derived mesenchymal stem cells differentiate to hepatic myofibroblasts by transforming growth factor-beta1 via sphingosine kinase/sphingosine 1-phosphate (S1P)/S1P receptor axis. Am J Pathol 2012, 181(1):85-97.
88. Shangguan L., Ti X., Krause U., Hai B., Zhao Y., Yang Z., et al. Inhibition of TGF-beta/Smad signaling by BAMBI blocks differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and abolishes their protumor effects. Stem Cells 2012, 30(12):2810-2819.
89. Quante M., Tu S.P., Tomita H., Gonda T., Wang S.S., Takashi S., et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011, 19(2):257-272.
90. Grubisha M.J., Cifuentes M.E., Hammes S.R., Defranco D.B. A local paracrine and endocrine network involving TGFbeta: Cox-2, ROS, and estrogen receptor beta influences reactive stromal cell regulation of prostate cancer cell motility. Mol Endocrinol 2012, 26(6):940-954.
91. Stuelten C.H., DaCosta Byfield S., Arany P.R., Karpova T.S., Stetler-Stevenson W.G., Roberts A.B. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. J Cell Sci 2005, 118(Pt 10):2143-2153.
92. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000, 14(2):163-176.
93. Lynch C.C., Matrisian L.M. Matrix metalloproteinases in tumor-host cell communication. Differentiation 2002, 70(9-10):561-573.
94. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17:463-516.
95. Eck S.M., Cote A.L., Winkelman W.D., Brinckerhoff C.E. CXCR4 and matrix metalloproteinase-1 are elevated in breast carcinoma-associated fibroblasts and in normal mammary fibroblasts exposed to factors secreted by breast cancer cells. Mol Cancer Res 2009, 7(7):1033-1044.
96. Zhuang Z., Zhou R., Xu X., Tian T., Liu Y., Lian P., et al. Clinical significance of integrin alphavbeta6 expression effects on gastric carcinoma invasiveness and progression via cancer-associated fibroblasts. Med Oncol 2013, 30(3):580.
97. Wipff P.J., Rifkin D.B., Meister J.J., Hinz B. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol 2007, 179(6):1311-1323.
98. Stuelten C.H., Busch J.I., Tang B., Flanders K.C., Oshima A., Sutton E., et al. Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer. PLoS One 2010, 5(3):e9832.
99. Martinez-Outschoorn U.E., Whitaker-Menezes D., Pavlides S., Chiavarina B., Bonuccelli G., Casey T., et al. The autophagic tumor stroma model of cancer or battery-operated tumor growth: a simple solution to the autophagy paradox. Cell Cycle 2010, 9(21):4297-4306.
100. Capparelli C., Chiavarina B., Whitaker-Menezes D., Pestell T.G., Pestell R.G., Hulit J., et al. CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts: fueling tumor growth via paracrine interactions, without an increase in neo-angiogenesis. Cell Cycle 2012, 11(19):3599-3610.
101. Capparelli C., Guido C., Whitaker-Menezes D., Bonuccelli G., Balliet R., Pestell T.G., et al. Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production. Cell Cycle 2012, 11(12):2285-2302.
102. Zhao X., He Y., Chen H. Autophagic tumor stroma: mechanisms and roles in tumor growth and progression. Int J Cancer 2013, 132(1):1-8.
103. Sotgia F., Martinez-Outschoorn U.E., Howell A., Pestell R.G., Pavlides S., Lisanti M.P. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol 2012, 7:423-467.
104. Guido C., Whitaker-Menezes D., Capparelli C., Balliet R., Lin Z., Pestell R.G., et al. Metabolic reprogramming of cancer-associated fibroblasts by TGF-beta drives tumor growth: connecting TGF-beta signaling with Warburg-like cancer metabolism and L-lactate production. Cell Cycle 2012, 11(16):3019-3035.
105. Capparelli C., Whitaker-Menezes D., Guido C., Balliet R., Pestell T.G., Howell A., et al. CTGF drives autophagy: glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. Cell Cycle 2012, 11(12):2272-2284.
106. Carito V., Bonuccelli G., Martinez-Outschoorn U.E., Whitaker-Menezes D., Caroleo M.C., Cione E., et al. Metabolic remodeling of the tumor microenvironment: migration stimulating factor (MSF) reprograms myofibroblasts toward lactate production, fueling anabolic tumor growth. Cell Cycle 2012, 11(18):3403-3414.
107. Kuperwasser C., Chavarria T., Wu M., Magrane G., Gray J.W., Carey L., et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA 2004, 101(14):4966-4971.
108. Bhowmick N.A., Chytil A., Plieth D., Gorska A.E., Dumont N., Shappell S., et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004, 303(5659):848-851.
109. Cheng N., Chytil A., Shyr Y., Joly A., Moses H.L. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol Cancer Res 2008, 6(10):1521-1533.
110. Fang W.B., Jokar I., Chytil A., Moses H.L., Abel T., Cheng N. Loss of one Tgfbr2 allele in fibroblasts promotes metastasis in MMTV: polyoma middle T transgenic and transplant mouse models of mammary tumor progression. Clin Exp Metastasis 2011, 28(4):351-366.
111. Xu B.J., Yan W., Jovanovic B., An A.Q., Cheng N., Aakre M.E., et al. Quantitative analysis of the secretome of TGF-beta signaling-deficient mammary fibroblasts. Proteomics 2010, 10(13):2458-2470.
112. Franco O.E., Jiang M., Strand D.W., Peacock J., Fernandez S., Jackson R.S., et al. Altered TGF-beta signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Res 2011, 71(4):1272-1281.
113. Achyut B.R., Bader D.A., Robles A.I., Wangsa D., Harris C.C., Ried T., et al. Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-beta signaling. PLoS Genet 2013, 9(2):e1003251.
114. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473(7347):298-307.
115. Lambrechts D., Lenz H.J., de Haas S., Carmeliet P., Scherer S.J. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 2013, 31(9):1219-1230.
116. Berz D., Wanebo H. Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors. J Surg Oncol 2011, 103(6):574-586.
117. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295(5564):2387-2392.
118. Rasanen K., Vaheri A. Activation of fibroblasts in cancer stroma. Exp Cell Res 2010, 316(17):2713-2722.
119. Dorman G., Cseh S., Hajdu I., Barna L., Konya D., Kupai K., et al. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs 2010, 70(8):949-964.
120. Wikberg M.L., Edin S., Lundberg I.V., Van Guelpen B., Dahlin A.M., Rutegard J., et al. High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumour Biol 2013, 34(2):1013-1020.
121. Gupta V., Bassi D.E., Simons J.D., Devarajan K., Al-Saleem T., Uzzo R.G., et al. Elevated expression of stromal palladin predicts poor clinical outcome in renal cell carcinoma. PLoS One 2011, 6(6):e21494.
122. Garin-Chesa P., Old L.J., Rettig W.J. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA 1990, 87(18):7235-7239.
123. Scott A.M., Wiseman G., Welt S., Adjei A., Lee F.T., Hopkins W., et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 2003, 9(5):1639-1647.
124. Hofheinz R.D., al-Batran S.E., Hartmann F., Hartung G., Jager D., Renner C., et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 2003, 26(1):44-48.
125. Lonning S., Mannick J., McPherson J.M. Antibody targeting of TGF-beta in cancer patients. Curr Pharm Biotechnol 2011, 12(12):2176-2189.
126. Hawinkels L.J., Ten Dijke P. Exploring anti-TGF-beta therapies in cancer and fibrosis. Growth Factors 2011, 29(4):140-152.
127. Musashi M., Yang Y.C., Paul S.R., Clark S.C., Sudo T., Ogawa M. Direct and synergistic effects of interleukin 11 on murine hemopoiesis in culture. Proc Natl Acad Sci USA 1991, 88(3):765-769.
128. Teramura M., Kobayashi S., Hoshino S., Oshimi K., Mizoguchi H. Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood 1992, 79(2):327-331.
129. Kraman M., Bambrough P.J., Arnold J.N., Roberts E.W., Magiera L., Jones J.O., et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010, 330(6005):827-830.
130. Akhurst R.J., Hata A. Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov 2012, 11(10):790-811.
131. Connolly E.C., Freimuth J., Akhurst R.J. Complexities of TGF-beta targeted cancer therapy. Int J Biol Sci 2012, 8(7):964-978.
132. Bogdahn U., Hau P., Stockhammer G., Venkataramana N.K., Mahapatra A.K., Suri A., et al. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 2011, 13(1):132-142.